Pure Global

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus - Trial NCT03086330

Access comprehensive clinical trial information for NCT03086330 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Completed. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 302 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT03086330
Phase 3
Completed
drug
Trial Details
ClinicalTrials.gov • NCT03086330
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus. A 30-week Randomised, Double-blind, Placebo-controlled Trial

Study Focus

Semaglutide

Interventional

drug

Sponsor & Location

Novo Nordisk A/S

Andalusia,Anniston,Glendale,Phoenix,Tempe,Little Rock,La Jolla,Lincoln,Northridge,Edgewater,Maitland,Lawrenceville,Woodstock,Hutchinson,Lexington,Baltimore,Troy,Jefferson City,Albany,Smithtown,West Se, Austria,Canada,Japan,Norway,Puerto Rico,Russian Federation,United States of America

Timeline & Enrollment

Phase 3

Mar 15, 2017

Aug 06, 2018

302 participants

Primary Outcome

Change in HbA1c

Summary

This trial is conducted in Asia, Europe and North America. The aim of the trial is to compare
 the effect of semaglutide s.c. 1.0 mg once-weekly versus placebo as add-on to sodium glucose
 co-transporter-2 inhibitor (SGLT-2i) monotherapy or in combination with either metformin or
 sulfonylurea on glycaemic control after 30 weeks of treatment in subjects with type 2
 diabetes. Subjects will remain on their pre-trial medication.

ICD-10 Classifications

Type 2 diabetes mellitus
Type 2 diabetes mellitus with other specified complications
Type 2 diabetes mellitus with unspecified complications
Type 2 diabetes mellitus without complications
Type 2 diabetes mellitus with multiple complications

Data Source

ClinicalTrials.gov

NCT03086330

Non-Device Trial